Skip to main content

Table 3 Treatment subtypes identified by combination of multiple component and clustering analyses

From: Multidimensional analyses to assess the relations between treatment choices by physicians and patients’ characteristics: the example of COPD

Treatment subgroups Description, frequency
1: Nebulised treatments Nebulised anticholinergics and/or beta2 agonists. Less frequently, nebulised corticosteroids.
One of the first two treatments was prescribed to 45.55% of patients.
2: Fixed combinations Combinations of long acting beta 2 agonist and corticosteroids.
These combinations were prescribed to 51.44% of patients.
3 : LABA and inhaled corticosteroids prescribed separately LABA and inhaled corticosteroids, co-prescribed in 91.2% of patients who receive one and/or the other outside of a fixed combination.
Such “separate associations” were prescribed to 16.03% of patients.
4: Non-invasive ventilation and oxygen therapy Ventilation or oxygen therapy. Respiratory support may be prescribed with respiratory rehabilitation.
One of the first two therapies was prescribed to 18.71% of patients.
5: Fixed combinations of short-acting anticholinergic and β2 agonist These treatments are not prescribed in patients who receive long acting anticholinergics. Prescription of a fixed combination of LABA and ICS is possible and independent (neither association nor exclusion).
These fixed combinations were prescribed to 29.85% of patients.
6: Flu and pneumococcal vaccines Flu or pneumococcal vaccines and antibiotics, sometimes associated with chest physiotherapy.
At least one of the two first vaccines and antibiotics were prescribed to 39.83% of patients.